DALLAS, Nov. 17, 2004 (PRIMEZONE) -- Mosaic Nutraceuticals (Pink Sheets:MCNJ) announced that it will launch its proprietary osteoarthritis formula called Joint-2-Life for retail and international distribution December 14. Distributors, retailers and physicians interested in this product can contact the company prior to this date to arrange pre-orders and obtain more information.
Mosaic plans to support the launch of Joint-2-Life with a multi-million dollar PR and advertising campaign. This campaign will help educate consumers about the numerous advantages the Joint-2-Life formula offers people in managing and treating their osteoarthritis problems naturally.
President of Mosaic Nutraceuticals, Charlie Townsend, said, "The initial response we have gotten from Joint-2-Life has been incredible. We have already arranged international distribution and have plans to take the osteoarthritis marketplace by storm. Joint-2-Life is the real deal and we feel it will be considered the natural osteoarthritis cure within the coming year."
Joint-2-Life combines glucosamine with a revolutionary patented ingredient called celadrin. By combining celadrin with glucosamine the typical results experienced by taking glucosamine alone is greatly magnified. The Joint-2-Life combination of celadrin and glucosamine provides rapid joint cushioning, alleviates inflammation quickly, and accelerates the re-building/building of damaged cartilage, helping restore the entire joint area. Joint-2-Life is available without a prescription and is very cost-effective.
Osteoarthritis is considered wear-and-tear arthritis and is a major health problem affecting America. It is currently estimated that 20.7 million Americans currently suffer from osteoarthritis and that osteoarthritis is responsible for a minimum of 7 million physician visits per year.
About Mosaic Nutraceuticals
Mosaic Nutraceuticals is located in Dallas, and its mission is to help enhance and improve the quality of life of its consumers through cutting-edge, highly unique dietary supplements and products. Mosaic plans to be a market leader in the nutritional field and will strive to grow its product line through dynamic innovation and acquisitions. The categories Mosaic plans to focus on include: osteoarthritis, pain relief, low-carbohydrate functional foods, cholesterol health, weight loss/appetite suppression, anti-aging and general wellness.
Vioxx and Merck are registered trademarks and property of their respective owners.
These statements have not been evaluated by the FDA. This product is not intended to treat, cure or prevent any disease.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the company with the Securities and Exchange Commission. The company cannot guarantee its future results, levels of activity, performance or achievements.
HTML: http://newsroom.eworldwire.com/wr/111704/10817.htm
PDF: http://newsroom.eworldwire.com/pdf/111704/10817.pdf
ONLINE NEWSROOM: http://newsroom.eworldwire.com/2508.htm